Featured Story | By Annalee Armstrong Arena Pharmaceuticals has been in need of a new R&D show since a phase 2 pain drug flopped earlier this year, and, now, the biotech has landed the biggest ticket in town: Pfizer. The Big Pharma will add Arena to its bill in a deal valued at $6.7 billion, bringing on a suite of immuno-inflammatory disease candidates that target patient populations with an unmet need. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Eli Lilly has inked a $380 million deal for access to multiple discovery-stage oncology programs from Foghorn Therapeutics. The co-development and co-commercialization agreement gives Lilly access to potential treatments targeting a mutation that is found in about 5% of all tumors. read more By Annalee Armstrong Inquiring minds have wanted to know: what does Pfizer, loaded up with buckets of cash from the successful COVID-19 vaccine Comirnaty, want to buy? Executives gave a preview of what else they want on an investor call to discuss the $6.7 billion acquisition of Arena Pharmaceuticals this morning. read more Sponsored by: Precision for Medicine As technologies and methodologies advance, so do the potential applications for biospecimens. In this article, we explore seven uses of FFPE, ranging from the common to the cutting-edge. read more By Nick Paul Taylor Responses to Johnson & Johnson’s BCMA CAR-T therapy are going on and on and on. After a median follow-up of 22 months, a phase 1b/2 clinical trial of the Legend Biotech-partnered cell therapy is yet to hit the median progression-free or overall survival, suggesting the drug has an edge over Bristol Myers Squibb’s rival product Abecma. read more By Annalee Armstrong After making headlines this summer with first-in-human gene editing results, Intellia’s next therapy has officially landed in the clinic in patients with hereditary angioedema. The company said Monday it had dosed the first patient in the phase 1/2 clinical trial of NTLA-2002. read more By Kyle LaHucik Iterum Therapeutics is hoping it can secure an FDA approval after getting rejected by the agency in July, but first it needs a medical leader in place. The biotech rehired Sailaja Puttagunta, M.D., a former vice president, to get its oral antibiotic through another trial in hopes of scoring an approval. read more By Kevin Dunleavy Australian biotech CSL is eying Vifor Pharma and the buyout could come as soon as Tuesday, The Australian reports. On Monday, amid speculation about the possible deal, CSL confirmed the talks. read more By Andrea Park,Conor Hale Even as 2021 looks to be a landmark year for medtech M&A, all signs point to 2022’s tally dwarfing this year's. M&A trends for 2022 will likely shake out into two broad categories: larger players looking for bolt-on deals and mid-size companies wanting to consolidate. And when it comes to who’s buying, the short answer is: everyone. read more By Arlene Weintraub Mount Sinai researchers discovered that cancer cells stay dormant by secreting a specific type of collagen protein into their environment. They believe the finding could inspire new methods for predicting and preventing cancer metastasis. read more By Robert King HHS released its unified agenda that details regulations it is planning for next year, including potential regulations for short-term plans and the 340B program. read more Resources Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: BBK Worldwide New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
